Table 1.
Baseline characteristics of study participants
| Variable | n (%) | Median (Range) |
|---|---|---|
| Male sex | 24 (57.1) | |
| Diagnosis | ||
| de novo AML | 17 (40.5) | |
| ALL | 12 (28.6) | |
| CML-AP | 2 (4.8) | |
| MDS overt AML | 10 (23.8) | |
| PCL | 1 (2.4) | |
| Cytogenetics | ||
| Intermediate | 17 | |
| Poor | 22 | |
| ECOG PS | ||
| 0 | 2 (4.8) | |
| 1 | 25 (59.5) | |
| 2 | 7 (16.7) | |
| 3 | 8 (19.0) | |
| Status at allo-HCT | ||
| Primary refractory/Refractory relapse/Untreated MDS overt AML | 7/32/3 | |
| No. chemo regimens prior allo-HCT | 6 (0-18) | |
| Time from diagnosis to allo-HCT (days) | 319 (23-3738) | |
| Marrow blasts at allo-HCT | 26.0 (0.2-100) | |
| Conditioning regimen | ||
| Intensified | 9 (21.4) | |
| Standard | 12 (28.6) | |
| Reduced-intensity | 7 (16.7) | |
| Reduced-intensity + cytoreductive chemotherapy | 14 (33.3) | |
| GVHD prophylaxis | ||
| None | 3 (7.1) | |
| Calcineurin inhibitor alone | 5 (11.9) | |
| Calcineurin inhibitor + sMTX | 32 (76.2) | |
| Calcineurin inhibitor + MMF | 2 (4.8) | |
| Donor (HLA-A, B and DRB1 antigens) | ||
| Matched related PB/BM | 10/2 | |
| Mismatched related PB/BM | 3/1 | |
| Matched unrelated BM | 19 | |
| Mismatched unrelated BM | 1 | |
| Umbilical cord blood | 6 |
allo-HCT: allogeneic hematopoietic cell transplantation; HLA: human leukocyte antigen; sMTX: short-term methotrexate; MMF: mycophenolate motefil; BM: bone marrow; PB: peripheral blood.